Structure−Activity Studies for a Novel Series of Tricyclic Substituted Hexahydrobenz[e]isoindole α1A Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)

Autor: Meyer, M. D., Altenbach, R. J., Basha, F. Z., Carroll, W. A., Condon, S., Elmore, S. W., Kerwin, J. F., Jr., Sippy, K. B., Tietje, K., Wendt, M. D., Hancock, A. A., Brune, M. E., Buckner, S. A., Drizin, I.

Publikováno v: Journal of Medicinal Chemistry; April 20, 2000, Vol. 43 Issue: 8 p1586-1603, 18p

Two Novel and Potent 3-[(o-Methoxyphenyl)piperazinylethyl]-5-phenylthieno[2,3-d]pyrimidine-2,4-diones Selective for the a1D Receptor

Autor: Carroll, W. A., Sippy, K. B., Esbenshade, T. A., Buckner, S. A., Hancock, A. A., Meyer, M. D.

Publikováno v: Bioorganic & Medicinal Chemistry Letters; 2001, Vol. 11 Issue: 9 p1119-1121, 3p

ChemInform Abstract: Synthesis and Pharmacological Characterization of A-80426: A Putative Novel Antidepressant Combining α-2 Antagonism with 5-HT Uptake Inhibition.

Autor: MEYER, M. D., HANCOCK, A. A., TIETJE, K., SIPPY, K. B., GIARDINA, W. J., KERWIN, J. F. JUN.

Publikováno v: ChemInform; Feb1996, Vol. 27 Issue 6, pno-no, 1p

Structure-activity studies for a novel series of bicyclic substituted hexahydrobenz[e]isoindole alpha1A adrenoceptor antagonists as potential agents for the symptomatic treatment of benign prostatic hyperplasia.

Autor: Meyer MD; Neurological and Urological Diseases Research, Pharmaceutical Products Division, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064, USA., Altenbach RJ, Bai H, Basha FZ, Carroll WA, Kerwin JF Jr, Lebold SA, Lee E, Pratt JK, Sippy KB, Tietje K, Wendt MD, Brune ME, Buckner SA, Hancock AA, Drizin I

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2001 Jun 07; Vol. 44 (12), pp. 1971-85.

Synthesis and pharmacological characterization of 3-[2-((3aR,9bR)-cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-1H-benz[e] isoindol-2-yl)ethyl]pyrido-[3',4':4,5]thieno[3,2-d]pyrimidine-2,4 (1H,3H)-dione (A-131701): a uroselective alpha 1A adrenoceptor antagonist for the symptomatic treatment of benign prostatic hyperplasia.

Autor: Meyer MD; Neurological and Urological Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064-3500, USA., Altenbach RJ, Basha FZ, Carroll WA, Drizin I, Elmore SW, Ehrlich PP, Lebold SA, Tietje K, Sippy KB, Wendt MD, Plata DJ, Plagge F, Buckner SA, Brune ME, Hancock AA, Kerwin JF Jr

Publikováno v: Journal of medicinal chemistry [J Med Chem] 1997 Sep 26; Vol. 40 (20), pp. 3141-3.